Shots:

• The P-III (SUPERNOVA) study investigates the safety & efficacy of sipavibart (300mg, IM, 2nd dose post 6mos. of initial dose) vs control (tixagevimab/cilgavimab or PBO) to prevent COVID-19 in immunocompromised patients (n=3,335)
• The study reached both the dual 1EPs incl. relative risk reduction of symptomatic COVID-19 caused by any SARS-CoV-2 variant and relative risk reduction of infections caused by SARS-CoV-2 variants without F456L mutation
• The drug was well-tolerated with balanced AEs between the sipavibart & control arm. Detailed findings will be highlighted at the upcoming medical conference. AstraZeneca is planning approval pathways with regulatory authorities

Ref: AstraZeneca | Image: AstraZeneca

Related News:- AstraZeneca Reports Data from the P-III (ECHO) Study of Calquence Combination Regimen for Mantle Cell Lymphoma

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com